This inventor holds 1 USPTO granted patent. Top assignees: Academia Sinica, National Taiwan University. Active years: 2018.
Company Filing History:
1 out of 726 
1 out of 1,391 
Years Active: 2018
Title: Potprommanee Laddawan: Innovator in Lung Cancer Biomarkers
Introduction
Potprommanee Laddawan is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of medical diagnostics, particularly in the area of lung cancer detection. His work focuses on developing innovative solutions that can aid in the early diagnosis and prognosis of lung cancers.
Latest Patents
Laddawan holds a patent for a lung cancer biomarker that is crucial for diagnosing early-stage lung cancers or predicting their prognosis. This invention involves a GM2AP protein, which serves as a key component in the diagnostic process. The method he developed allows for in vitro detection of this biomarker, enhancing the ability to identify lung cancer at its earliest stages.
Career Highlights
Throughout his career, Potprommanee Laddawan has worked with prestigious institutions such as Academia Sinica and National Taiwan University. His experience in these organizations has provided him with a solid foundation in research and innovation, enabling him to contribute effectively to the scientific community.
Collaborations
Laddawan has collaborated with esteemed colleagues, including Shui-Tein Chen and Chong-Jen Yu. These partnerships have fostered a collaborative environment that promotes the advancement of research in lung cancer diagnostics.
Conclusion
Potprommanee Laddawan's work in developing a lung cancer biomarker represents a significant advancement in medical diagnostics. His contributions are vital for improving early detection and prognosis of lung cancers, ultimately benefiting patients and the healthcare community.